echinacea

Botanicalexperimental

Echinacea angustifolia, the narrow-leaved purple coneflower or blacksamson echinacea, is a species of flowering plant in the family Asteraceae. It is native to North America, where it is widespread across much of the Great Plains of central Canada and the central United States, with additional populations in surrounding regions. — Wikipedia

Clinical trial activity

24 trials · 38 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
8
Phase 3
6
Phase 4
7

Earliest trial started Jul 1, 1999 (NCT00689468)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2001

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • echinacea
  • echinacea
  • echinacea
  • echinacea angustifolia
  • echinacea angustifolia
  • echinacea purpurea
  • echinaforce

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04999098Phase 4Sep 30, 2021A. Vogel AG, Biodome Clinical, Clinical Research Centre CONVEX, Medical University of Graz, Medistat Ltd., Israel
NCT04981314Phase 4Jun 18, 2021Laboratoires Arkopharma, SALUD (Servicio Aragonés de Salud), Spain, University of Santiago de Compostela
NCT05242718N/AJan 10, 2021Dicentra Inc., Immunoflex Therapeutics Inc., University of British Columbia
NCT05002179Phase 4Nov 20, 2020A. Vogel AG, Biodome Clinical, Bodimed, Clinical Research Centre CONVEX, d.s.h. statistical services GmbH, Medistat Ltd., Israel, VITA Hospital
NCT03812900Phase 2/Phase 3 (Phase 3)Nov 30, 2018Bioforce AG, Cantonal Hospital of St. Gallen, Labormedizinisches Zentrum Dr. Risch
NCT03463018Phase 2Jun 6, 2018EuroPharma, Inc., Simon Khechinashvili University
NCT03070314Phase 4Feb 20, 2017Bioforce AG, University of Zurich
NCT02971384Phase 3Nov 1, 2016Bioforce AG
NCT02345447Phase 3Oct 1, 2013University of Tuebingen
NCT01674374Phase 2May 1, 2013National Cancer Institute (NCI), State University of New York, Buffalo
NCT02134119N/AJan 1, 2012Texas Tech University, University of Georgia
NCT01347658Phase 1Apr 1, 2011Fundacio Lluita Contra la SIDA
NCT01396889N/AMay 1, 2010Hormozgan University of Medical Sciences
NCT01129128N/AMay 1, 2010National Center for Complementary and Integrative Health (NCCIH), University of Washington
NCT01046890Phase 4Jan 1, 2010Badalona Hospital Germans Trias i Pujol, IrsiCaixa, University of Barcelona
NCT01021995Phase 4Oct 1, 2009Bioforce AG
NCT00860795N/AMar 1, 2009National Center for Complementary and Integrative Health (NCCIH), University of Washington
NCT00773435N/ANov 1, 2008National Center for Complementary and Integrative Health (NCCIH), University of Washington
NCT00707902Phase 3Feb 1, 2006Bioforce AG
NCT00231218Phase 3Jan 1, 2006University of Rochester
Showing 20 of 24 trials
Page 1 / 2

Organizations

Research & Development (38)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Center for Complementary and Integrative Health (NCCIH)Government6231999
Bioforce AGFor profit5522006
University of WashingtonAcademic/Hospital4322000
A. Vogel AGFor profit2212020
Biodome ClinicalAcademic/Hospital2012020
Clinical Research Centre CONVEXFor profit2012020
Medistat Ltd., IsraelFor profit2012020
Badalona Hospital Germans Trias i PujolAcademic/Hospital1112010
BodimedAcademic/Hospital1012020
Cantonal Hospital of St. GallenAcademic/Hospital1012018
Clemson UniversityAcademic/Hospital1012001
Dicentra Inc.For profit1012021
d.s.h. statistical services GmbHFor profit1012020
EuroPharma, Inc.For profit1112018
Fundacio Lluita Contra la SIDAAcademic/Hospital1112011
Hormozgan University of Medical SciencesAcademic/Hospital1112010
Immunoflex Therapeutics Inc.For profit1112021
IrsiCaixaAcademic/Hospital1012010
Laboratoires ArkopharmaFor profit1012021
Labormedizinisches Zentrum Dr. RischAcademic/Hospital1012018
38 organizations
Page 1 / 2